Naviwala Saad Salim, Khan Waqas Ahmed, Shoaib Daania, Nafees Taha, Shakeel Muzammil, Rashid Yasmin Abdul
Department of Medical Oncology, The Aga Khan University, National Stadium Road, Karachi 74800, Pakistan.
Department of Pathology, The Aga Khan University, National Stadium Road Karachi, Karachi 74800, Pakistan.
Oxf Med Case Reports. 2025 Mar 28;2025(4):omaf009. doi: 10.1093/omcr/omaf009. eCollection 2025 Apr.
Non-small cell lung cancer, specifically adenocarcinoma, is amenable to targeted therapy for genetic alterations. The role of BRCA mutations in pathogenesis and the efficacy of PARP inhibitors in these cases are still unclear. This case involves a 61-year-old male patient with a past history of Hodgkin's Lymphoma and a heavy smoking history who developed lung adenocarcinoma and was found to have a BRCA2 mutation. Following disease progression on first-line chemotherapy and a detailed case discussion in the multidisciplinary team meeting, second-line Olaparib was started, but the patient's condition worsened rapidly, and he died from the illness. This case highlights the fact that BRCA mutations, though less common, are a potential target that should be explored further. Further large-scale studies are crucial to understanding and improving treatment outcomes for patients with BRCA-mutated NSCLC.
非小细胞肺癌，尤其是腺癌，对于基因改变适合进行靶向治疗。BRCA突变在发病机制中的作用以及PARP抑制剂在这些病例中的疗效仍不明确。本病例涉及一名61岁男性患者，既往有霍奇金淋巴瘤病史且有大量吸烟史，患肺腺癌，发现有BRCA2突变。在一线化疗疾病进展且多学科团队会议进行详细病例讨论后，开始使用二线奥拉帕尼，但患者病情迅速恶化，最终因病死亡。该病例凸显了一个事实，即BRCA突变虽不常见，但仍是一个应进一步探索的潜在靶点。进一步的大规模研究对于理解和改善BRCA突变的非小细胞肺癌患者的治疗结果至关重要。
